Your Messages Inbox
Your Article Summary
See Latest ArticlesPatent life of antiretroviral drugs approved in the US from 1987 to 2007
AIDS Care, 06/22/09
Rodriguez-Monguio R et al. - The effective patent life listed for the last patent of seven ARV NMEs exceeded 20 years. Shortening the drug approval process increased the effective patent life of ARVs and facilitated faster entry of new drugs into the market. ARVs had an average of 2-3 more years of effective patent life than other therapeutic classes and, therefore, a longer period without generic competition.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/08/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Article Search
Sponsor